FY2025 EPS Estimate for ADC Therapeutics Lifted by Analyst

ADC Therapeutics SA (NYSE:ADCT) – Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of ADC Therapeutics in a report issued on Thursday, May 15th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($1.99) per share for the year, up from their previous forecast of ($2.25). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share.

ADC Therapeutics (NYSE:ADCT) last issued its earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The company had revenue of $23.03 million during the quarter, compared to analysts’ expectations of $17.71 million.

A number of other analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of ADC Therapeutics in a report on Monday, March 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Thursday, May 15th. Guggenheim dropped their price objective on shares of ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 31st. Finally, Stephens raised their target price on shares of ADC Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ADC Therapeutics presently has a consensus rating of “Buy” and an average price target of $7.75.

ADC Therapeutics Stock Performance

ADCT stock opened at $2.15 on Monday. The company has a 50 day moving average price of $1.43 and a two-hundred day moving average price of $1.80. The stock has a market capitalization of $212.74 million, a P/E ratio of -0.90 and a beta of 1.54. ADC Therapeutics has a one year low of $1.05 and a one year high of $4.17.

Institutional Investors Weigh In On ADC Therapeutics

Institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC raised its position in shares of ADC Therapeutics by 31.6% in the fourth quarter. Orbimed Advisors LLC now owns 5,968,451 shares of the company’s stock valued at $11,877,000 after purchasing an additional 1,434,650 shares during the period. Woodline Partners LP acquired a new position in ADC Therapeutics in the 4th quarter valued at $3,848,000. Platinum Investment Management Ltd. raised its holdings in ADC Therapeutics by 11.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,612,556 shares of the company’s stock worth $3,209,000 after acquiring an additional 168,040 shares during the period. Geode Capital Management LLC lifted its position in ADC Therapeutics by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 963,109 shares of the company’s stock worth $1,917,000 after acquiring an additional 9,938 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in ADC Therapeutics during the 4th quarter worth $1,426,000. 41.10% of the stock is currently owned by institutional investors and hedge funds.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.